M. Groeppel

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

A. Muehler, H. Kohlhof, M. Groeppel, 2019, Drugs in R&D.

4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease†

C. Hofmann, L. Fitzpatrick, Jeffrey S. Small, 2010, Inflammatory bowel diseases.

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

A. Muehler, H. Kohlhof, M. Groeppel, 2020, European Journal of Drug Metabolism and Pharmacokinetics.

Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases

A. Muehler, H. Kohlhof, M. Groeppel, 2020, World journal of gastrointestinal pathophysiology.